Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: Therapeutic implications for dystrophic epidermolysis bullosa

Molecular Therapy

Volumn 22, Issue 10, 2014, Pages 1741-1752

  Cogan, Jon ^a   Weinstein, Jacqueline ^a   Wang, Xinyi ^a   Hou, Yingping ^a   Martin, Sabrina ^a   South, Andrew P ^b   Woodley, David T ^a   Chen, Mei ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC G 418; COLLAGEN TYPE 7; GENTAMICIN; MESSENGER RNA; NEOMYCIN; PAROMOMYCIN; TOBRAMYCIN; STOP CODON;

ARTICLE; CELL MOTILITY; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXPRESSION VECTOR; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; NONSENSE MUTATION; PREMATURE STOP CODON; RNA STABILITY; STOP CODON; TRANSIENT TRANSFECTION; DOSE RESPONSE; DRUG EFFECTS; EXTRACELLULAR SPACE; GENETICS; HEK293 CELL LINE; INTRACELLULAR SPACE; METABOLISM; MUTATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; TRANSFORMED CELL LINE;

AMINOGLYCOSIDES; CELL LINE, TRANSFORMED; CODON, NONSENSE; COLLAGEN TYPE VII; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXTRACELLULAR SPACE; FIBROBLASTS; HEK293 CELLS; HUMANS; INTRACELLULAR SPACE; KERATINOCYTES; MUTATION; PROTEIN BIOSYNTHESIS; PROTEIN TRANSPORT;

EID: 84925937581     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.140     Document Type: Article

References (48)

1. Lin, AN and Carter, DM (1992). Epidermolysis Bullosa: Basic and Clinical Aspects. Springer-Verlag New York, Inc: New York.
2. Uitto, J and Christiano, AM (1994). Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res 287: 16-22.
3. Uitto, J and Christiano, AM (1992). Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest 90: 687-692.
4. Parente, MG, Chung, LC, Ryynänen, J, Woodley, DT, Wynn, KC, Bauer, EA et al. (1991). Human type VII collagen: cDNA cloning and chromosomal mapping of the gene. Proc Natl Acad Sci USA 88: 6931-6935.
5. Burgeson, RE (1993). Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol 101: 252-255.
6. Sakai, LY, Keene, DR, Morris, NP and Burgeson, RE (1986). Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 103: 1577-1586.
7. Dang, N and Murrell, DF (2008). Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 17: 553-568.
8. Wertheim-Tysarowska, K, Sobczyń ska-Tomaszewska, A, Kowalewski, C, Skroń ski, M, Swięćkowski, G, Kutkowska-Kaźmierczak, A et al. (2012). The COL7A1 mutation database. Hum Mutat 33: 327-331.
9. Zingman, LV, Park, S, Olson, TM, Alekseev, AE and Terzic, A (2007). Aminoglycosideinduced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharmacol Ther 81: 99-103.
10. Barton-Davis, ER, Cordier, L, Shoturma, DI, Leland, SE and Sweeney, HL (1999). Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104: 375-381.
11. Bedwell, DM, Kaenjak, A, Benos, DJ, Bebok, Z, Bubien, JK, Hong, J et al. (1997). Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3: 1280-1284.
12. Linde, L and Kerem, B (2008). Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 24: 552-563.
13. Wagner, KR, Hamed, S, Hadley, DW, Gropman, AL, Burstein, AH, Escolar, DM et al. (2001). Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49: 706-711.
14. Kuschal, C, DiGiovanna, JJ, Khan, SG, Gatti, RA and Kraemer, KH (2013). Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons. Proc Natl Acad Sci USA 110: 19483-19488.
15. Nicholson, P, Yepiskoposyan, H, Metze, S, Zamudio Orozco, R, Kleinschmidt, N and Mühlemann, O (2010). Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci 67: 677-700.
16. Bidou, L, Allamand, V, Rousset, JP and Namy, O (2012). Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med 18: 679-688.
17. Chen, M, Kasahara, N, Keene, DR, Chan, L, Hoeffler, WK, Finlay, D et al. (2002). Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32: 670-675.
18. Contard, P, Bartel, RL, Jacobs, L 2nd, Perlish, JS, MacDonald, ED 2nd, Handler, L et al. (1993). Culturing keratinocytes and fibroblasts in a three-dimensional mesh results in epidermal differentiation and formation of a basal lamina-Anchoring zone. J Invest Dermatol 100: 35-39.
19. Woodley, DT, Keene, DR, Atha, T, Huang, Y, Lipman, K, Li, W et al. (2004). Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10: 693-695.
20. Woodley, DT, Krueger, GG, Jorgensen, CM, Fairley, JA, Atha, T, Huang, Y et al. (2003). Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121: 1021-1028.
21. Wong, T, Gammon, L, Liu, L, Mellerio, JE, Dopping-Hepenstal, PJ, Pacy, J et al. (2008). Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128: 2179-2189.
22. Woodley, DT, Keene, DR, Atha, T, Huang, Y, Ram, R, Kasahara, N et al. (2004). Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10: 318-326.
23. Remington, J, Wang, X, Hou, Y, Zhou, H, Burnett, J, Muirhead, T et al. (2009). Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17: 26-33.
24. Ortiz-Urda, S, Thyagarajan, B, Keene, DR, Lin, Q, Fang, M, Calos, MP et al. (2002). Stable nonviral genetic correction of inherited human skin disease. Nat Med 8: 1166-1170.
25. Woodley, DT, Wang, X, Amir, M, Hwang, B, Remington, J, Hou, Y et al. (2013). Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol 133: 1910-1913.
26. Woodley, DT, Remington, J, Huang, Y, Hou, Y, Li, W, Keene, DR et al. (2007). Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15: 628-635.
27. Wagner, JE, Ishida-Yamamoto, A, McGrath, JA, Hordinsky, M, Keene, DR, Woodley, DT et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363: 629-639.
28. Tidman, MJ and Eady, RA (1985). Evaluation of anchoring fibrils and other components of the dermal-epidermal junction in dystrophic epidermolysis bullosa by a quantitative ultrastructural technique. J Invest Dermatol 84: 374-377.
29. Fritsch, A, Loeckermann, S, Kern, JS, Braun, A, Bösl, MR, Bley, TA et al. (2008). A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 118: 1669-1679.
30. Swan, SK (1997). Aminoglycoside nephrotoxicity. Semin Nephrol 17: 27-33.
31. Forge, A and Schacht, J (2000). Aminoglycoside antibiotics. Audiol Neurootol 5: 3-22.
32. Kellermayer, R, Szigeti, R, Keeling, KM, Bedekovics, T and Bedwell, DM (2006). Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol 126: 229-231.
33. Shiozuka, M, Wagatsuma, A, Kawamoto, T, Sasaki, H, Shimada, K, Takahashi, Y et al. (2010). Transdermal delivery of a readthrough-inducing drug: a new approach of gentamicin administration for the treatment of nonsense mutation-mediated disorders. J Biochem 147: 463-470.
34. Brendel, C, Belakhov, V, Werner, H, Wegener, E, Gärtner, J, Nudelman, I et al. (2011). Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J Mol Med (Berl) 89: 389-398.
35. Houghton, JL, Green, KD, Chen, W and Garneau-Tsodikova, S (2010). The future of aminoglycosides: the end or renaissance? Chembiochem 11: 880-902.
36. Welch, EM, Barton, ER, Zhuo, J, Tomizawa, Y, Friesen, WJ, Trifillis, P et al. (2007). PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91.
37. Bordeira-Carrico, R, Pego, AP, Santos, M and Oliveira, C (2012). Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 18: 667-678.
38. Du, M, Liu, X, Welch, EM, Hirawat, S, Peltz, SW and Bedwell, DM (2008). PTC124 is an orally bioavailable compound that promotes suppression of the human CFTRG542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 105: 2064-2069.
39. McElroy, SP, Nomura, T, Torrie, LS, Warbrick, E, Gartner, U, Wood, G et al. (2013). A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 11: e1001593.
40. Keeling, KM and Bedwell, DM (2002). Clinically relevant aminoglycosides can suppress disease-Associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl) 80: 367-376.
41. Floquet, C, Hatin, I, Rousset, JP and Bidou, L (2012). Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. PLoS Genet 8: e1002608.
42. Boyce, ST and Ham, RG (1983). Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. J Invest Dermatol 81(suppl. 1): 33s-40s.
43. O'Keefe, EJ and Chiu, ML (1988). Stimulation of thymidine incorporation in keratinocytes by insulin, epidermal growth factor, and placental extract: comparison with cell number to assess growth. J Invest Dermatol 90: 2-7.
44. Normand, J and Karasek, MA (1995). A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin. In Vitro Cell Dev Biol Anim 31: 447-455.
45. Woodley, DT, Bachmann, PM and O'Keefe, EJ (1988). Laminin inhibits human keratinocyte migration. J Cell Physiol 136: 140-146.
46. Krueger, GG and Jorgensen, CM (1997). Defined system to assess the in vitro induction of a psoriasis phenotype on normal keratinocytes by fibroblasts from psoritic subjects. J Cutan Med Surg 2: 20-25.
47. Gammon, WR, Briggaman, RA, Inman, AO 3rd, Queen, LL and Wheeler, CE (1984). Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 82: 139-144.
48. Chen, M, Costa, FK, Lindvay, CR, Han, YP and Woodley, DT (2002). The recombinant expression of full-length type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa. J Biol Chem 277: 2118-2124.